goglides.dev
ResearchFinanceTechCompaniesDiscussion
Search
Sign inJoin
goglidesgoglides.devSocial learning for Finance and Tech.
TermsPrivacyDisclaimerModerationAcceptable UseDMCAContact
Company / Finance

Neurocrine Biosciences, Inc.

NBIX · UNKNOWN

Neurocrine reported FY2025 revenue of $2.86 billion and Q1 2026 revenue of $815 million, making the thesis about whether profitable neuroscience growth can broaden while pipeline and commercialization risk stay controlled.

Ask Question
Coverage BootstrapNASDAQNBIXNeurocrine Biosciences, Inc.
OverviewFinancialsResearchTimelineCompareValuationScorecardDiscussion
Latest ReportJul 22, 2026Neurocrine: the neuroscience cash engine still has to broaden beyond one franchiseView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 of 1 reports match
Clear filters
Selected tags
Coverage BootstrapNasdaq
Clear tags
MatchAny tagAll tags
Latest Thesis

Neurocrine: the neuroscience cash engine still has to broaden beyond one franchise

Neurocrine reported FY2025 revenue of $2.86 billion and Q1 2026 revenue of $815 million, making the thesis about whether profitable neuroscience growth can broaden while pipeline and commercialization risk stay controlled.

Jul 22, 20265 minSlides available
Read reportOpen slidesDiscussion (0)
Neurocrine Biosciences, Inc.the neuroscience cash engine still has to broaden beyond one fraJul 22, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
Neurocrine: the neuroscience cash engine still has to broaden beyond one franchiseNeurocrine reported FY2025 revenue of $2.86 billion and Q1 2026 revenue of $815 million, making the thesis about whether profitable neuroscience growth can broaden while pipeline and commercialization risk stay controlled.NASDAQJul 22, 20265 minReadSlides

Report Sources

No source records are attached to the current company reports.

FollowAdd to Watchlist